Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience

What It Covers

Nobel laureate Ardem Patapoutian, neuroscientist at Scripps Research, traces his path from war-torn Lebanon to discovering piezo1 and piezo2 ion channels — proteins that translate mechanical force into touch, proprioception, blood pressure regulation, and pain signals — and explains how these findings are now driving non-addictive peripheral pain drug development.

Key Questions Answered

• •Piezo2 loss-of-function clinical profile: Humans with non-functional piezo2 genes cannot sense touch, lack proprioception entirely, and lose bladder-filling sensation. These patients either compensate visually to walk or use wheelchairs. This clinical data, documented by NIH researchers Alex Chesler and Carsten Bonnemann, confirms piezo2 as the primary mechanical transducer for touch and body-position awareness in humans.
• •Peripheral pain targeting strategy: Blocking pain at the peripheral nervous system — via ion channels like piezo2 or Nav1.8 — avoids addiction pathways located in the brain. Vertex's Nav1.8 inhibitor Journavx received FDA approval using this principle. Patapoutian's lab targets piezo2 specifically for tactile allodynia, where normally non-painful touch becomes painful, without blocking protective acute pain responses.
• •Local application as drug delivery solution: Systemic piezo2 blockers would eliminate touch and proprioception across the body, making oral pills non-viable. Patapoutian's lab focuses on topical or localized delivery — targeting the bladder or specific tissue sites — to achieve therapeutic benefit while avoiding on-target side effects that would impair normal sensory function.
• •Reductionist screening methodology: Rather than working directly with difficult-to-manipulate sensory neurons, Patapoutian's team screened Neuro2a cells — a standard petri-dish cell line — for mechanical current responses. From a 300-candidate RNAi knockdown screen taking roughly two to three days per candidate, postdoc Bertrand Coest identified piezo1 at candidate number 72 after approximately one year of negative results.
• •Curiosity-driven research as drug discovery pipeline: Patapoutian's lab discovered piezo roles in macrophage phagocytosis, uterine contractions during childbirth, and blood pressure regulation — none originally targeted. This expanding application map emerged purely from following mechanosensation questions. The lab now uses in silico compound screening across billions of molecules to find piezo modulators, reporting meaningful progress in 2025 after a decade of limited chemical hits.
• •Career positioning in emerging institutional environments: Patapoutian chose Scripps Research in 2000 over more established neuroscience departments, gaining a joint appointment split between academic Scripps and the Novartis-funded Genomics Institute. This gave access to high-throughput genomics tools and a small-team, Bell Labs-style discovery model. The decision, widely criticized by senior colleagues at the time, provided infrastructure that directly enabled the piezo discovery.